SAN DIEGO, May 13, 2015 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of Accelerate Diagnostics Inc (Nasdaq:AXDX) over alleged Violations of Federal Securities Laws by Accelerate Diagnostics Inc in connection with certain allegedly false and misleading statements.
Investors who purchased (Nasdaq:AXDX) shares prior to March 2014 and continue to hold any of those shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff claims that between March 7, 2014 and February 17, 2015, defendants allegedly misrepresented and/or failed to disclose to investors that Accelerate Diagnostics’ main product the ID/AST system, formally known as the BACcel system, requires a positive blood culture to diagnose pathogens in a blood sample.
On February 18, 2015, an article was published that asserted that Accelerate Diagnostics Inc falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture, while in reality, the test required a blood culture, a fact that significantly reduced the value of the technology.
Those who purchased Accelerate Diagnostics Inc (Nasdaq:AXDX) shares have certain options and should contact the Shareholders Foundation, Inc. by e-mail at mail@shareholdersfoundation.com or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.